Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Conditions

• Recurrent Multiple Myeloma
• Refractory Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Iberdomide — DRUG
  Receive PO
• Belantamab Mafodotin — BIOLOGICAL
  Receive IV
• Dexamethasone — DRUG
  Receive PO
• Echocardiography — PROCEDURE
  Undergo ECHO
• Computed Tomography — PROCEDURE
  Undergo CT
• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Positron Emission Tomography — PROCEDURE
  Undergo PET
• Bone Marrow Biopsy — PROCEDURE
  Undergo Bone Marrow Biopsy
• Bone Marrow Aspiration — PROCEDURE
  Undergo Bone Marrow Aspirate
• Biospecimen Collection — PROCEDURE
  Undergo blood sample collection

Study Details

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.

Key Dates

Start date

Apr 23, 2025

Status verified

Mar 2026

Primary completion

May 1, 2028

Completion

Aug 1, 2030

Study Design

Enrollment

88 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Phase I (iberdomide, belantamab mafodotin, dexamethasone)
  Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
• Active Comparator: Phase II, Arm I (belantamab mafodotin, dexamethasone)
  Patients receive belantamab mafodotin IV on day 1 and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients who progress may cross over to Arm II. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
• Experimental: Phase II, Arm II (iberdomide, belantamab mafodotin)
  Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo bone marrow biopsy and aspiration and blood sample collection throughout trial.

Primary Outcome Measure

Maximum tolerated dose (MTD) of iberdomide (Phase I) [ Time Frame: During the first cycle of therapy, up to 28 days ]

Central Contacts

• Monique Hartley-Brown, MD
  857-215-1692
  [email protected]
• Destin Carlisle
  773-702-8824
  [email protected]

Locations (40)

Find similar trials in Ames, IA

Related Studies

• TriPRIL CAR T Cells in Multiple Myeloma
  PHASE1 · Recruiting · Marcela V. Maus, M.D.,Ph.D. · Boston, Massachusetts
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
  PHASE2 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
  PHASE1/PHASE2 · Recruiting · Indapta Therapeutics, INC. · Los Angeles, California
• Elranatamab in R/R Multiple Myeloma
  PHASE2 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts